<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39371366</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>08</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2328-8957</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Open forum infectious diseases</Title><ISOAbbreviation>Open Forum Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Highly Heterogeneous Kaposi Sarcoma-Associated Herpesvirus Oral Shedding Kinetics Among People With and Without Kaposi Sarcoma and Human Immunodeficiency Virus Coinfection.</ArticleTitle><Pagination><StartPage>ofae548</StartPage><MedlinePgn>ofae548</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">ofae548</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/ofid/ofae548</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">An improved understanding of oral Kaposi sarcoma-associated herpesvirus (KSHV) viral dynamics could provide insights into transmission risk and guide vaccine development.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We evaluated KSHV oral shedding dynamics in Ugandan adults stratified by Kaposi sarcoma (KS) and human immunodeficiency virus (HIV) status. Participants were followed for ≥4 weeks, with daily home oral swab collection to quantify KSHV using polymerase chain reaction. Shedding rates were defined by number of days with KSHV DNA detected divided by total days with swabs and compared by group using hurdle models.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Two hundred ninety-five participants were enrolled; median age was 35 years (range, 18-71 years), and 134 (45%) were male. KSHV was detected more frequently among participants with KS (HIV positive [HIV<sup>+</sup>]/KS<sup>+</sup>, 56/76 [74%]; HIV negative [HIV<sup>-</sup>]/KS<sup>+</sup>, 9/18 [50%]) than those without KS (HIV<sup>+</sup>/KS<sup>-</sup>, 36/125 [29%]; HIV<sup>-</sup>/KS<sup>-</sup>, 16/76 [21%]); odds of shedding did not differ significantly by HIV status. Among participants with KSHV detected, shedding rates did not differ significantly by group. Median per-participant viral loads among positive samples were lowest in HIV<sup>+</sup>/KS<sup>+</sup> (3.1 log<sub>10</sub> copies/mL) and HIV<sup>-</sup>/KS<sup>+</sup> (3.3 log<sub>10</sub> copies/mL) participants relative to HIV<sup>+</sup>/KS<sup>-</sup> (3.8 log<sub>10</sub> copies/mL) and HIV<sup>-</sup>/KS<sup>-</sup> (4.0 log<sub>10</sub> copies/mL) participants. All groups had participants with low viral load intermittent shedding and participants with high viral load persistent shedding. Within each group, individual KSHV shedding rate positively correlated with median KSHV log<sub>10</sub> copies/mL, and episode duration positively correlated with peak viral load.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">Oral KSHV shedding is highly heterogeneous across Ugandan adults with and without KS and HIV. Persistent shedding is associated with higher median viral loads regardless of HIV and KS status.</AbstractText><CopyrightInformation>© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Krantz</LastName><ForeName>Elizabeth M</ForeName><Initials>EM</Initials><Identifier Source="ORCID">0009-0000-0029-8511</Identifier><AffiliationInfo><Affiliation>Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mutyaba</LastName><ForeName>Innocent</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Uganda Cancer Institute, Kampala, Uganda.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nankoma</LastName><ForeName>Janet</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Uganda Cancer Institute, Kampala, Uganda.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okuku</LastName><ForeName>Fred</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Uganda Cancer Institute, Kampala, Uganda.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Casper</LastName><ForeName>Corey</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Access to Advanced Health Institute, Seattle, Washington, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Orem</LastName><ForeName>Jackson</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Uganda Cancer Institute, Kampala, Uganda.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Swan</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Phipps</LastName><ForeName>Warren</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0003-3564-8571</Identifier><AffiliationInfo><Affiliation>Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Access to Advanced Health Institute, Seattle, Washington, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schiffer</LastName><ForeName>Joshua T</ForeName><Initials>JT</Initials><AffiliationInfo><Affiliation>Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Open Forum Infect Dis</MedlineTA><NlmUniqueID>101637045</NlmUniqueID><ISSNLinking>2328-8957</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">HHV-8</Keyword><Keyword MajorTopicYN="N">HIV</Keyword><Keyword MajorTopicYN="N">KSHV</Keyword><Keyword MajorTopicYN="N">Kaposi sarcoma</Keyword><Keyword MajorTopicYN="N">viral shedding dynamics</Keyword></KeywordList><CoiStatement>Potential conflicts of interest. J. T. S. received consulting fees from Pfizer for advising on SARS-CoV-2 therapeutics and GlaxoSmithKline for advising on HSV vaccines. C. C. receives fees for consulting from Recordati Rare Disease, fees for sitting on the scientific advisory board of Viracta Therapeutics, and research funding from ImmunityBio and Janssen. All other authors report no potential conflicts.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>11</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>11</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>5</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39371366</ArticleId><ArticleId IdType="pmc">PMC11450676</ArticleId><ArticleId IdType="doi">10.1093/ofid/ofae548</ArticleId><ArticleId IdType="pii">ofae548</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cook  RD, Hodgson  TA, Waugh  ACW, et al.  Mixed patterns of transmission of human herpesvirus-8 (Kaposi’s sarcoma-associated herpesvirus) in Malawian families. J Gen Virol  2002; 83(Pt 7):1613–9.</Citation><ArticleIdList><ArticleId IdType="pubmed">12075079</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor  MM, Chohan  B, Lavreys  L, et al.  Shedding of human herpesvirus 8 in oral and genital secretions from HIV-1-seropositive and -seronegative Kenyan women. J Infect Dis  2004; 190:484–8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6768555</ArticleId><ArticleId IdType="pubmed">15243920</ArticleId></ArticleIdList></Reference><Reference><Citation>Mbulaiteye  SM, Pfeiffer  RM, Engels  EA, et al.  Detection of Kaposi sarcoma–associated herpesvirus DNA in saliva and buffy-coat samples from children with sickle cell disease in Uganda. J Infect Dis  2004; 190:1382–6.</Citation><ArticleIdList><ArticleId IdType="pubmed">15378429</ArticleId></ArticleIdList></Reference><Reference><Citation>Dedicoat  M, Newton  R, Alkharsah  KR, et al.  Mother-to-child transmission of human herpesvirus-8 in South Africa. J Infect Dis  2004; 190:1068–75.</Citation><ArticleIdList><ArticleId IdType="pubmed">15319855</ArticleId></ArticleIdList></Reference><Reference><Citation>Shebl  FM, Emmanuel  B, Bunts  L, et al.  Population-based assessment of Kaposi sarcoma–associated herpesvirus DNA in plasma among Ugandans. J Med Virol  2013; 85:1602–10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3755768</ArticleId><ArticleId IdType="pubmed">23852686</ArticleId></ArticleIdList></Reference><Reference><Citation>Olp  LN, Shea  DM, White  MK, Gondwe  C, Kankasa  C, Wood  C. Early childhood infection of Kaposi’s sarcoma-associated herpesvirus in Zambian households: a molecular analysis. Int J Cancer  2013; 132:1182–90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3535687</ArticleId><ArticleId IdType="pubmed">22815207</ArticleId></ArticleIdList></Reference><Reference><Citation>Phipps  W, Saracino  M, Selke  S, et al.  Oral HHV-8 replication among women in Mombasa, Kenya. J Med Virol  2014; 86:1759–65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4289619</ArticleId><ArticleId IdType="pubmed">24692069</ArticleId></ArticleIdList></Reference><Reference><Citation>Bender Ignacio  RA, Goldman  JD, Magaret  AS, et al.  Patterns of human herpesvirus-8 oral shedding among diverse cohorts of human herpesvirus-8 seropositive persons. Infect Agent Cancer  2016; 11:7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4748452</ArticleId><ArticleId IdType="pubmed">26865856</ArticleId></ArticleIdList></Reference><Reference><Citation>Newton  R, Labo  N, Wakeham  K, et al.  Determinants of gammaherpesvirus shedding in saliva among Ugandan children and their mothers. J Infect Dis  2018; 218:892–900.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6093317</ArticleId><ArticleId IdType="pubmed">29762709</ArticleId></ArticleIdList></Reference><Reference><Citation>Labo  N, Marshall  V, Miley  W, et al.  Mutual detection of Kaposi’s sarcoma-associated herpesvirus and Epstein-Barr virus in blood and saliva of Cameroonians with and without Kaposi’s sarcoma. Int J Cancer  2019; 145:2468–77.</Citation><ArticleIdList><ArticleId IdType="pubmed">31265124</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalwoga  A, Nakibuule  M, Marshall  V, et al.  Risk factors for Kaposi’s sarcoma–associated herpesvirus DNA in blood and in saliva in rural Uganda. Clin Infect Dis  2020; 71:1055–62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7428384</ArticleId><ArticleId IdType="pubmed">31555829</ArticleId></ArticleIdList></Reference><Reference><Citation>Casper  C, Carrell  D, Miller  KG, et al.  HIV serodiscordant sex partners and the prevalence of human herpesvirus 8 infection among HIV negative men who have sex with men: baseline data from the EXPLORE study. Sex Transm Infect  2006; 82:229–35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2564745</ArticleId><ArticleId IdType="pubmed">16731675</ArticleId></ArticleIdList></Reference><Reference><Citation>Pauk  J, Huang  ML, Brodie  SJ, et al.  Mucosal shedding of human herpesvirus 8 in men. N Engl J Med  2000; 343:1369–77.</Citation><ArticleIdList><ArticleId IdType="pubmed">11070101</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnston  C, Orem  J, Okuku  F, et al.  Impact of HIV infection and Kaposi sarcoma on human herpesvirus-8 mucosal replication and dissemination in Uganda. PLoS One  2009; 4:e4222.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2625442</ArticleId><ArticleId IdType="pubmed">19156206</ArticleId></ArticleIdList></Reference><Reference><Citation>Casper  C, Krantz  E, Selke  S, et al.  Frequent and asymptomatic oropharyngeal shedding of human herpesvirus 8 among immunocompetent men. J Infect Dis  2007; 195:30–6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2128060</ArticleId><ArticleId IdType="pubmed">17152006</ArticleId></ArticleIdList></Reference><Reference><Citation>Matrajt  L, Gantt  S, Mayer  BT, et al.  Virus and host-specific differences in oral human herpesvirus shedding kinetics among Ugandan women and children. Sci Rep  2017; 7:13105.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5638921</ArticleId><ArticleId IdType="pubmed">29026166</ArticleId></ArticleIdList></Reference><Reference><Citation>Schiffer  JT, Magaret  A, Selke  S, Corey  L, Wald  A. Detailed analysis of mucosal herpes simplex virus-2 replication kinetics with and without antiviral therapy. J Antimicrob Chemother  2011; 66:2593–600.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3191945</ArticleId><ArticleId IdType="pubmed">21865349</ArticleId></ArticleIdList></Reference><Reference><Citation>Schiffer  JT, Wald  A, Selke  S, Corey  L, Magaret  A. The kinetics of mucosal herpes simplex virus-2 infection in humans: evidence for rapid viral–host interactions. J Infect Dis  2011; 204:554–61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3144170</ArticleId><ArticleId IdType="pubmed">21791657</ArticleId></ArticleIdList></Reference><Reference><Citation>Schiffer  JT, Swan  D, Al Sallaq  R, et al.  Rapid localized spread and immunologic containment define herpes simplex virus-2 reactivation in the human genital tract. Elife  2013; 2:e00288.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3629793</ArticleId><ArticleId IdType="pubmed">23606943</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayer  BT, Matrajt  L, Casper  C, et al.  Dynamics of persistent oral cytomegalovirus shedding during primary infection in Ugandan infants. J Infect Dis  2016; 214:1735–43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5144733</ArticleId><ArticleId IdType="pubmed">27651417</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayer  BT, Krantz  EM, Swan  D, et al.  Transient oral human cytomegalovirus infections indicate inefficient viral spread from very few initially infected cells. J Virol  2017; 91:e00380-17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5446638</ArticleId><ArticleId IdType="pubmed">28381570</ArticleId></ArticleIdList></Reference><Reference><Citation>Byrne  CM, Johnston  C, Orem  J, et al.  Examining the dynamics of Epstein-Barr virus shedding in the tonsils and the impact of HIV-1 coinfection on daily saliva viral loads. PLoS Comput Biol  2021; 17:e1009072.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8248743</ArticleId><ArticleId IdType="pubmed">34153032</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadinoto  V, Shapiro  M, Sun  CC, Thorley-Lawson  DA. The dynamics of EBV shedding implicate a central role for epithelial cells in amplifying viral output. PLoS Pathog  2009; 5:e1000496.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2698984</ArticleId><ArticleId IdType="pubmed">19578433</ArticleId></ArticleIdList></Reference><Reference><Citation>Schiffer  JT, Swan  DA, Magaret  A, Schacker  TW, Wald  A, Corey  L. Mathematical modeling predicts that increased HSV-2 shedding in HIV-1 infected persons is due to poor immunologic control in Ganglia and genital mucosa. PLoS One  2016; 11:e0155124.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4902308</ArticleId><ArticleId IdType="pubmed">27285483</ArticleId></ArticleIdList></Reference><Reference><Citation>Magaret  AS, Wald  A, Huang  ML, Selke  S, Corey  L. Optimizing PCR positivity criterion for detection of herpes simplex virus DNA on skin and mucosa. J Clin Microbiol  2007; 45:1618–20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1865863</ArticleId><ArticleId IdType="pubmed">17329447</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu  MC, Pavlicova  M, Nunes  EV. Zero-inflated and hurdle models of count data with extra zeros: examples from an HIV-risk reduction intervention trial. Am J Drug Alcohol Abuse  2011; 37:367–75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3238139</ArticleId><ArticleId IdType="pubmed">21854279</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng  CX. A comparison of zero-inflated and hurdle models for modeling zero-inflated count data. J Stat Distrib Appl  2021; 8:8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8570364</ArticleId><ArticleId IdType="pubmed">34760432</ArticleId></ArticleIdList></Reference><Reference><Citation>Seaman  S, Pavlou  M, Copas  A. Review of methods for handling confounding by cluster and informative cluster size in clustered data. Stat Med  2014; 33:5371–87.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4320764</ArticleId><ArticleId IdType="pubmed">25087978</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler  LM, Were  WA, Balinandi  S, et al.  Human herpesvirus 8 infection in children and adults in a population-based study in rural Uganda. J Infect Dis  2011; 203:625–34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3071279</ArticleId><ArticleId IdType="pubmed">21273188</ArticleId></ArticleIdList></Reference><Reference><Citation>Wakeham  K, Webb  EL, Sebina  I, et al.  Risk factors for seropositivity to Kaposi sarcoma–associated herpesvirus among children in Uganda. J Acquir Immune Defic Syndr  2013; 63:228–33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3707567</ArticleId><ArticleId IdType="pubmed">23403859</ArticleId></ArticleIdList></Reference><Reference><Citation>Newton  R, Labo  N, Wakeham  K, et al.  Kaposi sarcoma–associated herpesvirus in a rural Ugandan cohort, 1992–2008. J Infect Dis  2018; 217:263–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5853224</ArticleId><ArticleId IdType="pubmed">29099933</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalwoga  A, Webb  EL, Chihota  B, et al.  Kaposi’s sarcoma–associated herpesvirus seropositivity is associated with parasite infections in Ugandan fishing communities on Lake Victoria islands. PLoS Negl Trop Dis  2019; 13:e0007776.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6816576</ArticleId><ArticleId IdType="pubmed">31618208</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalwoga  A, Webb  EL, Muserere  C, et al.  Variation in KSHV prevalence between geographically proximate locations in Uganda. Infect Agent Cancer  2020; 15:49.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7376633</ArticleId><ArticleId IdType="pubmed">32714434</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayer  BT, Krantz  EM, Wald  A, et al.  Estimating the risk of human herpesvirus 6 and cytomegalovirus transmission to Ugandan infants from viral shedding in saliva by household contacts. Viruses  2020; 12:171.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7077293</ArticleId><ArticleId IdType="pubmed">32028569</ArticleId></ArticleIdList></Reference><Reference><Citation>Boucoiran  I, Mayer  BT, Krantz  EM, et al.  Nonprimary maternal cytomegalovirus infection after viral shedding in infants. Pediatr Infect Dis J  2018; 37:627–31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6016842</ArticleId><ArticleId IdType="pubmed">29889809</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>